Jump to content

Encore: Denosumab topic corrected


Recommended Posts

An earlier version of this topic suggested that the FDA had given approval to the use of Denosumab (Xgeva) in castrate resistant prostate cancer (CRPC) to prevent or delay bone metastases.

In fact, on 8 February 2012, a FDA panel recommended against this use.

While the panel found that denosumab "prolongs bone metastasis-free survival by reducing the risk of developing bone metastases", they recommended that this difference in bone metastasis-free survival was modest and did not outweigh the risks of treatment, namely osteonecrosis of the jaw.

The original FDA approval to delay skeletal events in bone-metastatic disease remains in place.

Denosumab is also approved in Australia for this use , and is available under the PBS.

Read the corrected topic here:



Corrected article

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...